Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
ceo Processed

Dane Stevens & Optimi Health

8 shared events · Importance 3 · Last updated Sep 23, 2026

Importance
3
Shared Events
8
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard

Dane Stevens is the Chief Executive Officer and Co-Founder of Optimi Health, a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products. He leads the company's strategic direction and clinical development.

84
Business
Dane Stevens: Dane Stevens, CEO of Optimi Health, highlighted the significance of the production and export runs in expanding access to psychedelic treatments in Australia.
Optimi Health: Optimi Health completed the first 2026 production and export of MDMA and psilocybin capsules to Australia, expanding its market access for psychedelic treatments for PTSD and TRD.
Jan 26, 2026 · 6 articles
84
Business
Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, is leading the company's ibogaine initiative and highlights the growing interest and public funding for ibogaine research.
Optimi Health: Optimi Health has secured ibogaine supply and is commencing development of finished drug products, positioning itself as a key supplier in the emerging psychedelic therapy market.
Jun 08, 2026 · 14 articles
71
Tech
Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health Corp., announced the launch of the new microdose psilocybin products, highlighting their consistent dosage for controlled research.
Optimi Health: Optimi Health Corp. has launched new microdose psilocybin products, expanding its product range and market reach for clinical research and therapeutic programs internationally. This development is expected to positively impact the company's revenue and market position.
Jun 16, 2026 · 11 articles
63
Business
Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, highlighted the significance of the company's first shipment to the United Kingdom and its unique position as a vertically integrated GMP supplier.
Optimi Health: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.
Jun 02, 2026 · 25 articles
63
Business
Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, expressed pride in the company's commercial supply of psilocybin and highlighted Australia's role as a model for regulated psychedelic medicine.
Optimi Health: Optimi Health completed its third commercial shipment of psilocybin to Australia, expanding its market presence and generating recurring revenue from the sale of its psychedelic drug products for medical use.
Jun 29, 2026 · 12 articles
63
Tech
Dane Stevens: As CEO and Co-Founder of Optimi Health, Dane Stevens announced the trial and emphasized its strategic importance. His leadership is tied to the company's clinical development strategy.
Optimi Health: Optimi Health is the central entity initiating the Phase 2 trial, which represents its largest clinical commitment to date and a strategic step toward potential drug registration. The trial could enhance its pipeline and market positioning, though it carries development risks and no near-term revenue.
Sep 10, 2026 · 15 articles
62
Business
Dane Stevens: As CEO and co-founder, he announced and commented on the appointment, highlighting its importance for the company's clinical trials.
Optimi Health: The company made the appointment to strengthen its clinical development capabilities ahead of planned Phase 2 psilocybin and Phase 3 MDMA trials. The move supports its pipeline but has limited near-term financial impact.
Sep 22, 2026 · 7 articles
45
Business
Dane Stevens: Dane Stevens is identified as CEO of Optimi Health and the investor contact for the company; he is not reported to have a specific speaking role at the conference.
Optimi Health: Optimi Health is the central entity of the event, announcing its participation in the H.C. Wainwright 28th Annual Global Investment Conference and making its presentation available on demand from September 11, 2026. The event offers the company a platform to engage investors, though no financial or clinical news was disclosed.
Sep 08, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Dane Stevens and Optimi Health interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.